KPTI Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
35.1M
+2.9%
34.1M
-22.6%
44.0M
+16.1%
37.9M
+26.4%
30.0M
Cost of Revenue
1.3M
-9.4%
1.5M
-29.8%
2.1M
+101.0%
1.1M
-19.2%
1.3M
Gross Profit
33.7M
+3.5%
32.6M
-22.3%
41.9M
+13.7%
36.9M
+28.4%
28.7M
Operating Expenses
60.5M
+19.9%
50.4M
-11.7%
57.2M
-6.7%
61.3M
-1.1%
62.0M
R&D
33.8M
+22.2%
27.7M
-9.4%
30.5M
-6.8%
32.8M
-5.3%
34.6M
SG&A
26.7M
+17.2%
22.8M
-14.4%
26.6M
-6.6%
28.5M
+4.1%
27.4M
Operating Income
-26760000
-50.0%
-17844000
-17.2%
-15220000
+37.6%
-24387000
+26.7%
-33256000
EBITDA
-26748000
-50.1%
-17825000
-18.1%
-15099000
+37.9%
-24309000
+26.7%
-33178000
Net Income
-22392000
+78.1%
-102198000
-208.5%
-33127000
+11.1%
-37252000
-58.8%
-23462000
EPS (Basic)
$-1.02
+85.4%
$-7.00
-83.2%
$-3.82
+11.6%
$-4.32
-56.0%
$-2.77
EPS (Diluted)
$-1.24
+82.3%
$-7.00
-83.2%
$-3.82
+11.6%
$-4.32
-56.0%
$-2.77
Shares (Diluted)
24.7M
+126.0%
10.9M
+26.1%
8.7M
+0.6%
8.6M
+1.8%
8.5M
Karyopharm Therapeutics (KPTI) โ€” Financials